BiotechTube

AZD6615 + Placebo

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyslipidemia

Conditions

Dyslipidemia

Trial Timeline

Jul 24, 2019 → Feb 10, 2020

NCT ID
NCT04055168

About AZD6615 + Placebo

AZD6615 + Placebo is a phase 1 stage product being developed by AstraZeneca for Dyslipidemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04055168. Target conditions include Dyslipidemia.

What happened to similar drugs?

15 of 20 similar drugs in Dyslipidemia were approved

Approved (15) Terminated (3) Active (3)
✅Pitavastatin + PravastatinEli LillyApproved
✅Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
✅rosuvastatin + placebo + rosuvastatin + atorvastatinAstraZenecaApproved
✅FluvastatinNovartisApproved
✅Fluvastatin extended release, fenofibrate + Fixed combination simvastatin/ezetimibeNovartisApproved
✅FluvastatinNovartisApproved
✅Atorvastatin + AtorvastatinPfizerApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04055168Phase 1Terminated

Competing Products

20 competing products in Dyslipidemia

See all competitors
ProductCompanyStageHype Score
LY3202328 + Placebo + Atorvastatin + SimvastatinEli LillyPhase 1
29
Pitavastatin + PravastatinEli LillyApproved
43
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
43
YH14755 + Metformin + RosuvastatinYuhanPhase 3
40
YHR1705 + YHR1706 + YHR1705+YHR1706YuhanPhase 1
29
Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapyYuhanPre-clinical
33
Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDCYuhanPhase 1
29
MevalotinDaiichi SankyoPre-clinical
26
PravastatinDaiichi SankyoPre-clinical
26
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SCEli LillyPhase 1
29
LY3885125 + PlaceboEli LillyPhase 1
21
LY3561774 + PlaceboEli LillyPhase 1
29
LY2484595 + Atorvastatin + Simvastatin + Rosuvastatin + Placebo for LY2484595 + Placebo for StatinsEli LillyPhase 2
35
LY3561774 + PlaceboEli LillyPhase 2
35
LY2484595 + Placebo + AtorvastatinEli LillyPhase 2
35
EvacetrapibEli LillyPhase 1
29
PPAR alpha + placeboEli LillyPhase 2
35
AZD0780 + Ezetimibe + Rosuvastatin + Bempedoic Acid + PlaceboAstraZenecaPhase 1
29
ABT-335 + RosuvastatinAstraZenecaPhase 1
29
AZD0780 + AZD0780 + AZD0780 + Placebo + Placebo + Placebo + RosuvastatinAstraZenecaPhase 1
29